BRAF and cancer: Thus, a BRAF V600E mutation induces dysregulation of the MAPKpathway, which is responsible for cell proliferation and differentiation, in thyroidfollicular cells, ultimately producing an aggressive PTC with a very poor prognosis.The mechanism underlying the role of dabrafenib in treating PTC has been associatedwith targeting the proteins (RAF kinases) produced by the BRAF V600E mutation, whichresults in MEK phosphorylation, cell cycle arrest and cancer cell apoptosis(35).